Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Coadministration has not been studied. Vancomycin is eliminated unchanged predominantly via glomerular filtration, and there is little potential for a pharmacokinetic interaction with emtricitabine and tenofovir due to competition for active renal transport mechanisms. However, both vancomycin and tenofovir-DF are potentially nephrotoxic and tenofovir-DF should be avoided with concurrent or recent use of a nephrotoxic agent. If concomitant use of emtricitabine/tenofovir-DF and nephrotoxic agents is unavoidable, renal function should be closely monitored. A case study described renal failure in 2 patients taking tenofovir-DF and a prolonged course of vancomycin.
Use of emtricitabine/tenofovir-DF should be avoided with concurrent or recent use of a nephrotoxic medicinal product like vancomycin.
Truvada Summary of Product Characteristics Gilead Sciences Ltd, June 2018.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking